BIOPHARMA
By
Can Gilead’s $260 Million AI Investment in 2025 — Backed by Strategic AI Initiatives — Accelerate Discovery, R&D, and Commercial Impact in 2026?
Global – December 31, 2025 — Gilead Sciences, Inc. expanded its commitment to artificial intelligence (AI) throughout 2025…
Can Sanofi’s $380 Million AI Investment in 2025 — Bolstered by Strategic Partnerships — Drive Breakthroughs in Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Sanofi S.A. made significant investments in artificial intelligence (AI) across discovery, clinical…
Can Roche’s $420 Million AI Investment in 2025 — Backed by Strategic AI Deals — Boost Discovery, R&D, and Commercial Advantage in 2026?
Global – December 31, 2025 — Roche Holding AG, a global leader in pharmaceuticals and diagnostics, significantly expanded…
Can Novartis’ $480 Million AI Investment in 2025 — Bolstered by Strategic AI Deals — Accelerate Discovery, R&D, and Commercial Leadership in 2026?
Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial intelligence (AI) across…
Did Abivax Just Quash Acquisition Rumors by Eli Lilly — and What It Means for Its IBD Breakthrough Asset?
January 26, 2026 — Paris & Global — Abivax SA, the French clinical‑stage biotechnology company, this week publicly dismissed speculation…
Could Sun Pharma’s Bold Bid for Organon Redefine Its U.S. Strategy and Global Footprint?
January 25, 2026 — Mumbai & New York — Sun Pharmaceutical Industries Ltd. (Sun Pharma), India’s largest pharmaceutical company, has…
